The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...

Cigna is reducing monthly out-of-pocket costs to $200 for patients using weight-loss drugs Wegovy and Zepbound. These ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.